

Cory Berkland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11398804/publications.pdf>

Version: 2024-02-01

109
papers

5,839
citations

76326

40
h-index

79698

73
g-index

109
all docs

109
docs citations

109
times ranked

7625
citing authors

#	ARTICLE	IF	CITATIONS
1	Soluble Antigen Arrays Efficiently Deliver Peptides and Arrest Spontaneous Autoimmune Diabetes. <i>Diabetes</i> , 2021, 70, 1334-1346.	0.6	11
2	CCR2 signaling in breast carcinoma cells promotes tumor growth and invasion by promoting CCL2 and suppressing CD154 effects on the angiogenic and immune microenvironments. <i>Oncogene</i> , 2020, 39, 2275-2289.	5.9	24
3	Soluble Antigen Arrays for Selective Desensitization of Insulin-Reactive B Cells. <i>Molecular Pharmaceutics</i> , 2019, 16, 1563-1572.	4.6	14
4	Role of ALDH1A1 and HTRA2 expression to CCL2/CCR2 mediated breast cancer cell growth and invasion. <i>Biology Open</i> , 2019, 8, .	1.2	15
5	Soluble Antigen Arrays Displaying Mimotopes Direct the Response of Diabetogenic T Cells. <i>ACS Chemical Biology</i> , 2019, 14, 1436-1448.	3.4	9
6	Formulation and preclinical evaluation of a toll-like receptor 7/8 agonist as an anti-tumoral immunomodulator. <i>Journal of Controlled Release</i> , 2019, 306, 165-176.	9.9	48
7	Acute B-Cell Inhibition by Soluble Antigen Arrays Is Valency-Dependent and Predicts Immunomodulation in Splenocytes. <i>Biomacromolecules</i> , 2019, 20, 2115-2122.	5.4	7
8	Controlled release of poly(vinyl sulfonate) scale inhibitor to extend reservoir treatment lifetime. <i>Journal of Applied Polymer Science</i> , 2019, 136, 47225.	2.6	10
9	Design of a Cytocompatible Hydrogel Coating to Modulate Properties of Ceramic-Based Scaffolds for Bone Repair. <i>Cellular and Molecular Bioengineering</i> , 2018, 11, 211-217.	2.1	20
10	Application of Polyelectrolyte Complex Nanoparticles to Increase the Lifetime of Poly Vinyl Sulfonate Scale Inhibitor. , 2018, , .		7
11	Soluble antigen arrays disarm antigen-specific B cells to promote lasting immune tolerance in experimental autoimmune encephalomyelitis. <i>Journal of Autoimmunity</i> , 2018, 93, 76-88.	6.5	31
12	Screening Immunomodulators To Skew the Antigen-Specific Autoimmune Response. <i>Molecular Pharmaceutics</i> , 2017, 14, 66-80.	4.6	6
13	Multivalent Soluble Antigen Arrays Exhibit High Avidity Binding and Modulation of B Cell Receptor-Mediated Signaling to Drive Efficacy against Experimental Autoimmune Encephalomyelitis. <i>Biomacromolecules</i> , 2017, 18, 1893-1907.	5.4	22
14	Co-delivery of autoantigen and dexamethasone in incomplete Freund's adjuvant ameliorates experimental autoimmune encephalomyelitis. <i>Journal of Controlled Release</i> , 2017, 266, 156-165.	9.9	13
15	Strategies to develop endogenous stem cell-recruiting bioactive materials for tissue repair and regeneration. <i>Advanced Drug Delivery Reviews</i> , 2017, 120, 50-70.	13.7	119
16	Pulmonary Administration of Soluble Antigen Arrays Is Superior to Antigen in Treatment of Experimental Autoimmune Encephalomyelitis. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 3293-3302.	3.3	18
17	Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment. <i>Oncotarget</i> , 2016, 7, 49349-49367.	1.8	95
18	Hyaluronic Acid Molecular Weight Determines Lung Clearance and Biodistribution after Instillation. <i>Molecular Pharmaceutics</i> , 2016, 13, 1904-1914.	4.6	30

#	ARTICLE	IF	CITATIONS
19	Formulation and Characterization of Nanocluster Ceftazidime for the Treatment of Acute Pulmonary Melioidosis. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 3399-3408.	3.3	9
20	Overcoming formulation challenges for the next generation of vaccines. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1501-1502.	5.0	0
21	Development and Characterization of FLT3-Specific Curcumin-Loaded Polymeric Micelles as a Drug Delivery System for Treating FLT3-Overexpressing Leukemic Cells. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 3645-3657.	3.3	15
22	Antigen-Specific Binding of Multivalent Soluble Antigen Arrays Induces Receptor Clustering and Impedes B Cell Receptor Mediated Signaling. <i>Biomacromolecules</i> , 2016, 17, 710-722.	5.4	22
23	Combining antigen and immunomodulators: Emerging trends in antigen-specific immunotherapy for autoimmunity. <i>Advanced Drug Delivery Reviews</i> , 2016, 98, 86-98.	13.7	66
24	Molecular Dynamics of Multivalent Soluble Antigen Arrays Support a Two-Signal Co-delivery Mechanism in the Treatment of Experimental Autoimmune Encephalomyelitis. <i>Molecular Pharmaceutics</i> , 2016, 13, 330-343.	4.6	13
25	Routes of Administration and Dose Optimization of Soluble Antigen Arrays in Mice with Experimental Autoimmune Encephalomyelitis. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 714-721.	3.3	17
26	NanoCluster Itraconazole Formulations Provide a Potential Engineered Drug Particle Approach to Generate Effective Dry Powder Aerosols. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2015, 28, 341-352.	1.4	14
27	Multivalent Nanomaterials: Learning from Vaccines and Progressing to Antigen-Specific Immunotherapies. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 346-361.	3.3	37
28	Pulmonary Delivery of Vancomycin Dry Powder Aerosol to Intubated Rabbits. <i>Molecular Pharmaceutics</i> , 2015, 12, 2665-2674.	4.6	16
29	The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 309-320.	2.5	30
30	Codelivery of antigen and an immune cell adhesion inhibitor is necessary for efficacy of soluble antigen arrays in experimental autoimmune encephalomyelitis. <i>Molecular Therapy - Methods and Clinical Development</i> , 2014, 1, 14008.	4.1	35
31	Structure, Size, and Solubility of Antigen Arrays Determines Efficacy in Experimental Autoimmune Encephalomyelitis. <i>AAPS Journal</i> , 2014, 16, 1185-1193.	4.4	26
32	Co-Delivery of Autoantigen and B7 Pathway Modulators Suppresses Experimental Autoimmune Encephalomyelitis. <i>AAPS Journal</i> , 2014, 16, 1204-1213.	4.4	26
33	DNA complexed with TAT peptide and condensed using calcium possesses unique structural features compared to PEI polyplexes. <i>International Journal of Pharmaceutics</i> , 2014, 465, 11-17.	5.2	8
34	Hyaluronic acid colloidal gels as self-assembling elastic biomaterials. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2014, 102, 612-618.	3.4	16
35	NanoClusters Surface Area Allows Nanoparticle Dissolution with Microparticle Properties. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1787-1798.	3.3	12
36	Hyaluronic Acid Graft Polymers Displaying Peptide Antigen Modulate Dendritic Cell Response in Vitro. <i>Molecular Pharmaceutics</i> , 2014, 11, 367-373.	4.6	16

#	ARTICLE	IF	CITATIONS
37	NanoCluster budesonide formulations enable efficient drug delivery driven by mechanical ventilation. <i>International Journal of Pharmaceutics</i> , 2014, 462, 19-28.	5.2	14
38	Hybrid Hydroxyapatite Nanoparticle Colloidal Gels are Injectable Fillers for Bone Tissue Engineering. <i>Tissue Engineering - Part A</i> , 2013, 19, 2586-2593.	3.1	69
39	Synthesis and characterization of poly(<i>N</i> -vinyl formamide) hydrogels—A potential alternative to polyacrylamide hydrogels. <i>Journal of Polymer Science Part A</i> , 2013, 51, 435-445.	2.3	7
40	Single-step grafting of aminoxy-peptides to hyaluronan: A simple approach to multifunctional therapeutics for experimental autoimmune encephalomyelitis. <i>Journal of Controlled Release</i> , 2013, 168, 334-340.	9.9	30
41	Hyaluronic Acid Nanoparticles Titrate the Viscoelastic Properties of Viscosupplements. <i>Langmuir</i> , 2013, 29, 5123-5131.	3.5	25
42	Poly(vinylamine) microgels: pH-responsive particles with high primary amine contents. <i>Soft Matter</i> , 2013, 9, 3920.	2.7	31
43	Intratracheal Administration of a Nanoparticle-Based Therapy with the Angiotensin II Type 2 Receptor Gene Attenuates Lung Cancer Growth. <i>Cancer Research</i> , 2012, 72, 2057-2067.	0.9	68
44	Vaccine-like Controlled-Release Delivery of an Immunomodulating Peptide To Treat Experimental Autoimmune Encephalomyelitis. <i>Molecular Pharmaceutics</i> , 2012, 9, 979-985.	4.6	65
45	Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice. <i>Nanomedicine</i> , 2012, 7, 1297-1309.	3.3	39
46	Development of Budesonide Nanocluster Dry Powder Aerosols: Processing. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 3425-3433.	3.3	11
47	Development of Budesonide Nanocluster Dry Powder Aerosols: Formulation and Stability. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 3445-3455.	3.3	16
48	Development of Budesonide Nanocluster Dry Powder Aerosols: Preformulation. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 3434-3444.	3.3	10
49	Chemically modifiable fluorinated copolymer nanoparticles for ¹⁹ F-MRI contrast enhancement. <i>Journal of Applied Polymer Science</i> , 2012, 126, 1218-1227.	2.6	8
50	Calcium condensed cell penetrating peptide complexes offer highly efficient, low toxicity gene silencing. <i>International Journal of Pharmaceutics</i> , 2012, 427, 134-142.	5.2	50
51	Nanocluster Budesonide Formulations Enhance Drug Delivery through Endotracheal Tubes. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 1063-1072.	3.3	12
52	Nanoparticles Targeting Dendritic Cell Surface Molecules Effectively Block T Cell Conjugation and Shift Response. <i>ACS Nano</i> , 2011, 5, 1693-1702.	14.6	22
53	Particle Engineering Technologies for Pulmonary Drug Delivery. , 2011, , 283-312.		5
54	Noncovalent PEGylation by Polyanion Complexation as a Means To Stabilize Keratinocyte Growth Factor-2 (KGF-2). <i>Biomacromolecules</i> , 2011, 12, 3880-3894.	5.4	26

#	ARTICLE	IF	CITATIONS
55	Calcium Condensed LABL-TAT Complexes Effectively Target Gene Delivery to ICAM-1 Expressing Cells. <i>Molecular Pharmaceutics</i> , 2011, 8, 788-798.	4.6	38
56	Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 44, 522-533.	4.0	35
57	Controlling Ligand Surface Density Optimizes Nanoparticle Binding to ICAM-1. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 1045-1056.	3.3	78
58	Calcium Condensation of DNA Complexed with Cell-Penetrating Peptides Offers Efficient, Noncytotoxic Gene Delivery. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 1637-1642.	3.3	34
59	PLGA- ϵ -chitosan/PLGA- ϵ -alginate nanoparticle blends as biodegradable colloidal gels for seeding human umbilical cord mesenchymal stem cells. <i>Journal of Biomedical Materials Research - Part A</i> , 2011, 96A, 520-527.	4.0	126
60	Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics. <i>Therapeutic Delivery</i> , 2011, 2, 873-889.	2.2	20
61	Research Spotlight: Therapeutic Particles and Biomaterials Technology Laboratory at The University of Kansas. <i>Therapeutic Delivery</i> , 2010, 1, 29-35.	2.2	0
62	LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery. <i>Current Pharmaceutical Design</i> , 2010, 16, 2321-2330.	1.9	18
63	Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent. <i>International Journal of Pharmaceutics</i> , 2010, 391, 305-312.	5.2	28
64	Next Steps for Pharmaceutical Nanotechnology. <i>Journal of Pharmaceutical Innovation</i> , 2010, 5, 70-71.	2.4	1
65	Three-dimensional macroscopic scaffolds with a gradient in stiffness for functional regeneration of interfacial tissues. <i>Journal of Biomedical Materials Research - Part A</i> , 2010, 94A, 870-876.	4.0	38
66	Effects of divalent cations, seawater, and formation brine on positively charged polyethylenimine/dextran sulfate/chromium(III) polyelectrolyte complexes and partially hydrolyzed polyacrylamide/chromium(III) gelation. <i>Journal of Applied Polymer Science</i> , 2010, 115, 1008-1014.	2.6	33
67	Low charge polyvinylamine nanogels offer sustained, low-level gene expression. <i>Journal of Applied Polymer Science</i> , 2010, 118, 1921-1932.	2.6	5
68	Cationic surface modification of PLG nanoparticles offers sustained gene delivery to pulmonary epithelial cells. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 2413-2422.	3.3	28
69	Fluorinated Copolymer Nanoparticles for Multimodal Imaging Applications. <i>Macromolecular Rapid Communications</i> , 2010, 31, 87-92.	3.9	14
70	Microsphere-based scaffolds for cartilage tissue engineering: Using subcritical CO ₂ as a sintering agent. <i>Acta Biomaterialia</i> , 2010, 6, 137-143.	8.3	85
71	Injectable PLGA based colloidal gels for zero-order dexamethasone release in cranial defects. <i>Biomaterials</i> , 2010, 31, 4980-4986.	11.4	159
72	Production and characterization of polymer microspheres containing trace explosives using precision particle fabrication technology. <i>Journal of Microencapsulation</i> , 2010, 27, 426-435.	2.8	11

#	ARTICLE	IF	CITATIONS
73	Reduction of diffusion barriers in isolated rat islets improves survival, but not insulin secretion or transplantation outcome. <i>Organogenesis</i> , 2010, 6, 115-124.	1.2	58
74	Over-expression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells. <i>Cancer Biology and Therapy</i> , 2010, 9, 277-285.	3.4	58
75	cIBR Effectively Targets Nanoparticles to LFA-1 on Acute Lymphoblastic T Cells. <i>Molecular Pharmaceutics</i> , 2010, 7, 146-155.	4.6	14
76	Agglomerates of Ciprofloxacin Nanoparticles Yield Fine Dry Powder Aerosols. <i>Journal of Pharmaceutical Innovation</i> , 2010, 5, 79-87.	2.4	28
77	Iodinated NanoClusters as an Inhaled Computed Tomography Contrast Agent for Lung Visualization. <i>Molecular Pharmaceutics</i> , 2010, 7, 1274-1282.	4.6	32
78	Controlled release of Repifermin [®] from polyelectrolyte complexes stimulates endothelial cell proliferation. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 268-280.	3.3	28
79	Budesonide Nanoparticle Agglomerates as Dry Powder Aerosols With Rapid Dissolution. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 2731-2746.	3.3	76
80	Adhesion of pancreatic beta cells to biopolymer films. <i>Biopolymers</i> , 2009, 91, 676-685.	2.4	44
81	Combination Chemotherapeutic Dry Powder Aerosols via Controlled Nanoparticle Agglomeration. <i>Pharmaceutical Research</i> , 2009, 26, 1752-1763.	3.5	73
82	“Soft” Calcium Crosslinks Enable Highly Efficient Gene Transfection Using TAT Peptide. <i>Pharmaceutical Research</i> , 2009, 26, 2619-2629.	3.5	34
83	Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. <i>International Journal of Pharmaceutics</i> , 2009, 369, 136-143.	5.2	65
84	Magnetic resonance imaging of contrast-enhanced polyelectrolyte complexes. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2008, 4, 30-40.	3.3	23
85	Poly(<i>D,L</i> -lactide-co-glycolide) Nanoparticle Agglomerates as Carriers in Dry Powder Aerosol Formulation of Proteins. <i>Langmuir</i> , 2008, 24, 9775-9783.	3.5	22
86	Nanotechnology in vaccine delivery. <i>Advanced Drug Delivery Reviews</i> , 2008, 60, 915-928.	13.7	479
87	Delayed HPAM Gelation via Transient Sequestration of Chromium in Polyelectrolyte Complex Nanoparticles. <i>Macromolecules</i> , 2008, 41, 4398-4404.	4.8	76
88	Pure Insulin Nanoparticle Agglomerates for Pulmonary Delivery. <i>Langmuir</i> , 2008, 24, 13614-13620.	3.5	53
89	PLGA Nanoparticle [~] Peptide Conjugate Effectively Targets Intercellular Cell-Adhesion Molecule-1. <i>Bioconjugate Chemistry</i> , 2008, 19, 145-152.	3.6	176
90	Poly(<i>N</i> -vinylformamide) Nanogels Capable of pH-Sensitive Protein Release. <i>Macromolecules</i> , 2008, 41, 6546-6554.	4.8	83

#	ARTICLE	IF	CITATIONS
91	Microsphere-Based Seamless Scaffolds Containing Macroscopic Gradients of Encapsulated Factors for Tissue Engineering. <i>Tissue Engineering - Part C: Methods</i> , 2008, 14, 299-309.	2.1	106
92	Strategies and Applications for Incorporating Physical and Chemical Signal Gradients in Tissue Engineering. <i>Tissue Engineering - Part B: Reviews</i> , 2008, 14, 341-366.	4.8	170
93	Polyelectrolyte Complexes Stabilize and Controllably Release Vascular Endothelial Growth Factor. <i>Biomacromolecules</i> , 2007, 8, 1607-1614.	5.4	100
94	Biodegradable Nanoparticle Flocculates for Dry Powder Aerosol Formulation. <i>Langmuir</i> , 2007, 23, 10897-10901.	3.5	53
95	Acid-Labile Polyvinylamine Micro- and Nanogel Capsules. <i>Macromolecules</i> , 2007, 40, 4635-4643.	4.8	60
96	Macromolecule Release from Monodisperse PLG Microspheres: Control of Release Rates and Investigation of Release Mechanism. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 1176-1191.	3.3	56
97	NanoCipro encapsulation in monodisperse large porous PLGA microparticles. <i>Journal of Controlled Release</i> , 2007, 121, 100-109.	9.9	115
98	Monodisperse Liquid-filled Biodegradable Microcapsules. <i>Pharmaceutical Research</i> , 2007, 24, 1007-1013.	3.5	57
99	Cell Adhesion Molecules for Targeted Drug Delivery. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 1856-1872.	3.3	108
100	In vitro degradation of polyanhydride/polyester core-shell double-wall microspheres. <i>International Journal of Pharmaceutics</i> , 2005, 301, 294-303.	5.2	18
101	Modeling small-molecule release from PLG microspheres: effects of polymer degradation and nonuniform drug distribution. <i>Journal of Controlled Release</i> , 2005, 103, 149-158.	9.9	144
102	Microsphere size, precipitation kinetics and drug distribution control drug release from biodegradable polyanhydride microspheres. <i>Journal of Controlled Release</i> , 2004, 94, 129-141.	9.9	170
103	Uniform double-walled polymer microspheres of controllable shell thickness. <i>Journal of Controlled Release</i> , 2004, 96, 101-111.	9.9	120
104	Three-month, zero-order piroxicam release from monodispersed double-walled microspheres of controlled shell thickness. <i>Journal of Biomedical Materials Research Part B</i> , 2004, 70A, 576-584.	3.1	47
105	Controlling surface nano-structure using flow-limited field-injection electrostatic spraying (FFESS) of poly(L-lactide-co-glycolide). <i>Biomaterials</i> , 2004, 25, 5649-5658.	11.4	108
106	Precision Polymer Microparticles for Controlled-Release Drug Delivery. <i>ACS Symposium Series</i> , 2004, , 197-213.	0.5	5
107	PLG microsphere size controls drug release rate through several competing factors. <i>Pharmaceutical Research</i> , 2003, 20, 1055-1062.	3.5	182
108	Precise control of PLG microsphere size provides enhanced control of drug release rate. <i>Journal of Controlled Release</i> , 2002, 82, 137-147.	9.9	348

#	ARTICLE	IF	CITATIONS
109	Fabrication of PLG microspheres with precisely controlled and monodisperse size distributions. Journal of Controlled Release, 2001, 73, 59-74.	9.9	314